RxDoctor Payments Data

Rebecca Rich, APRN

Family · Easley, SCNPI 1740809458

Payments from drug & device makers

$5,235in general payments, 2019–2025

Across 102 payments — averaging $51.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$448
  • Incyte Corporation$427
  • Daiichi Sankyo Inc.$332
  • Pharmacosmos Therapeutics Inc.$306
  • Bayer$293
  • Gilead$283
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$4,88093%
  • Education$3567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,235 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$30,829
Medicare patients
233
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$13,683
Exemestane17$3,980
Anastrozole74$1,557
Tamoxifen Citrate23$688
Letrozole26$587
Dexamethasone15$558
Lidocaine-PrilocaineLidocaine/Prilocaine32$332
Potassium Chloride23$300
Promethazine Hcl15$231
Ondansetron Hcl22$227
Prochlorperazine Maleate13$196
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$117
Levothyroxine Sodium15$115
Lorazepam13$62
Prednisone15$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$13,68322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Easley

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →